BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 27029752)

  • 1. Clear cell carcinoma of the ovary: molecular insights and future therapeutic perspectives.
    Mabuchi S; Sugiyama T; Kimura T
    J Gynecol Oncol; 2016 May; 27(3):e31. PubMed ID: 27029752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy.
    Li M; Li H; Liu F; Bi R; Tu X; Chen L; Ye S; Cheng X
    J Ovarian Res; 2017 Feb; 10(1):9. PubMed ID: 28187748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced expression of Annexin A4 in clear cell carcinoma of the ovary and its association with chemoresistance to carboplatin.
    Kim A; Enomoto T; Serada S; Ueda Y; Takahashi T; Ripley B; Miyatake T; Fujita M; Lee CM; Morimoto K; Fujimoto M; Kimura T; Naka T
    Int J Cancer; 2009 Nov; 125(10):2316-22. PubMed ID: 19598262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical Efficacy for AKT Targeting in Clear Cell Carcinoma of the Ovary.
    Sasano T; Mabuchi S; Kuroda H; Kawano M; Matsumoto Y; Takahashi R; Hisamatsu T; Sawada K; Hashimoto K; Isobe A; Testa JR; Kimura T
    Mol Cancer Res; 2015 Apr; 13(4):795-806. PubMed ID: 25519148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clear cell carcinoma compared to serous carcinoma in early ovarian cancer: same prognosis in a large randomized trial.
    Timmers PJ; Zwinderman AH; Teodorovic I; Vergote I; Trimbos JB
    Int J Gynecol Cancer; 2009 Jan; 19(1):88-93. PubMed ID: 19258948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of autophagy protein LC3A as a therapeutic target in ovarian clear cell carcinomas.
    Miyamoto M; Takano M; Aoyama T; Soyama H; Yoshikawa T; Tsuda H; Furuya K
    J Gynecol Oncol; 2017 May; 28(3):e33. PubMed ID: 28382796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low response rate of second-line chemotherapy for recurrent or refractory clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma Study.
    Takano M; Sugiyama T; Yaegashi N; Sakuma M; Suzuki M; Saga Y; Kuzuya K; Kigawa J; Shimada M; Tsuda H; Moriya T; Yoshizaki A; Kita T; Kikuchi Y
    Int J Gynecol Cancer; 2008; 18(5):937-42. PubMed ID: 18081792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical Investigations of PM01183 (Lurbinectedin) as a Single Agent or in Combination with Other Anticancer Agents for Clear Cell Carcinoma of the Ovary.
    Takahashi R; Mabuchi S; Kawano M; Sasano T; Matsumoto Y; Kuroda H; Kozasa K; Hashimoto K; Sawada K; Kimura T
    PLoS One; 2016; 11(3):e0151050. PubMed ID: 26986199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glypican-3 expression predicts poor clinical outcome of patients with early-stage clear cell carcinoma of the ovary.
    Umezu T; Shibata K; Kajiyama H; Yamamoto E; Nawa A; Kikkawa F
    J Clin Pathol; 2010 Nov; 63(11):962-6. PubMed ID: 20972242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clear cell carcinoma of the ovary: is there a role of histology-specific treatment?
    Takano M; Tsuda H; Sugiyama T
    J Exp Clin Cancer Res; 2012 Jun; 31(1):53. PubMed ID: 22655678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential role of mTORC2 as a therapeutic target in clear cell carcinoma of the ovary.
    Hisamatsu T; Mabuchi S; Matsumoto Y; Kawano M; Sasano T; Takahashi R; Sawada K; Ito K; Kurachi H; Schilder RJ; Testa JR; Kimura T
    Mol Cancer Ther; 2013 Jul; 12(7):1367-77. PubMed ID: 23615631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor effects of interleukin-6 (IL-6)/interleukin-6 receptor (IL-6R) signaling pathway inhibition in clear cell carcinoma of the ovary.
    Yanaihara N; Hirata Y; Yamaguchi N; Noguchi Y; Saito M; Nagata C; Takakura S; Yamada K; Okamoto A
    Mol Carcinog; 2016 May; 55(5):832-41. PubMed ID: 25856562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of cisplatin resistance in clear cell carcinoma of the ovary.
    Itamochi H; Kigawa J; Akeshima R; Sato S; Kamazawa S; Takahashi M; Kanamori Y; Suzuki M; Ohwada M; Terakawa N
    Oncology; 2002; 62(4):349-53. PubMed ID: 12138243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Salvage chemotherapy for recurrent or persistent clear cell carcinoma of the ovary: a single-institution experience for a series of 20 patients.
    Yoshino K; Enomoto T; Fujita M; Ueda Y; Kimura T; Kobayashi E; Tsutsui T; Kimura T
    Int J Clin Oncol; 2013 Feb; 18(1):148-53. PubMed ID: 22160560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma.
    Itamochi H; Kigawa J; Terakawa N
    Cancer Sci; 2008 Apr; 99(4):653-8. PubMed ID: 18377417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemistry expression of targeted therapies biomarkers in ovarian clear cell and endometrioid carcinomas (type I) and endometriosis.
    Barreta A; Sarian LO; Ferracini AC; Costa LBE; Mazzola PG; de Angelo Andrade L; Derchain S
    Hum Pathol; 2019 Mar; 85():72-81. PubMed ID: 30447298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Redox-active iron-induced oxidative stress in the pathogenesis of clear cell carcinoma of the ovary.
    Yamada Y; Shigetomi H; Onogi A; Haruta S; Kawaguchi R; Yoshida S; Furukawa N; Nagai A; Tanase Y; Tsunemi T; Oi H; Kobayashi H
    Int J Gynecol Cancer; 2011 Oct; 21(7):1200-7. PubMed ID: 21885986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical Activity of Plitidepsin Against Clear Cell Carcinoma of the Ovary.
    Miyake R; Yamanaka S; Matsubara S; Mabuchi S
    Anticancer Res; 2021 Sep; 41(9):4277-4285. PubMed ID: 34475047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bevacizumab in recurrent ovarian cancer: could it be particularly effective in patients with clear cell carcinoma?
    Gallego A; Ramon-Patino J; Brenes J; Mendiola M; Berjon A; Casado G; Castelo B; Espinosa E; Hernandez A; Hardisson D; Feliu J; Redondo A
    Clin Transl Oncol; 2021 Mar; 23(3):536-542. PubMed ID: 32651885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MEK1/2 inhibitor selumetinib (AZD6244) inhibits growth of ovarian clear cell carcinoma in a PEA-15-dependent manner in a mouse xenograft model.
    Bartholomeusz C; Oishi T; Saso H; Akar U; Liu P; Kondo K; Kazansky A; Krishnamurthy S; Lee J; Esteva FJ; Kigawa J; Ueno NT
    Mol Cancer Ther; 2012 Feb; 11(2):360-9. PubMed ID: 22144664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.